(Clovis Oncology Inc. )

	CLVS latest price $32.4800 (0.84%) ($31.8200 - $32.8200) on Thu. Sep. 20, 2018.
	Trend Analysis and Forecast
Average Daily Percentage Swing	0% (three month average)
RSI	24
Latest Price	$32.4800(0.84%)
Stocks Behave Similarly	Similar Stock List
Weekly Trend	CLVS declines -4.8% a week on average for past two weeks.
Market Behavior	Broad based rally for large cap. Broad based rally for small cap.
Correlated ETFs	Broad market will support CLVS advance at 0% a week (0% probability)   XBI(14%)    IBB(13%)    ARKG(11%)    ARKK(11%)    XRT(10%)
Factors Impacting CLVS price	CLVS will advance at least -0% in a week (0% probabilities).   VIXM(-6%)    GDXJ(-6%)    SHY(-4%)    IFRA(-3%)    TLT(-2%)
Relative Volatility	(options are extremely cheap)
Market Trend Strength	0% (StdDev 0%)
Hourly BBV	0 ()
Intraday Trend	0.4%

Resistance Level	$34.3
5 Day Moving Average	$0(INF%)
10 Day Moving Average	$32.98(-1.52%)
20 Day Moving Average	$34.3(-5.31%)
To recent high	-34.4%
To recent low	2.2%
Market Cap	$2.865b

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

getNextHourMoveProbability failed